XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.23.2

Segment Information | 6 Months Ended
--- | ---
Jul. 01, 2023
Segment Reporting [Abstract] |
Segment Information | Segment Information The Company operates through its biotechnology segment for continuing operations. The biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment included all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The recycling segment also included byproduct revenue, which was primarily generated through the recycling of appliances. The technology segment designed wireless modules to connect devices to the Mobile Internet of Things (“IoT”) which contained location-based service (“LBS”) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers. As discussed above (see Note 3), the recycling and technology segments are being presented as discontinued operations for the 13 and 26 weeks ended July 1, 2023 and July 2, 2022. The following tables present our segment information for the 13 and 26 weeks ended July 1, 2023 and July 2, 2022 (in $000’s):
| Thirteen Weeks Ended |  | Twenty-Six Weeks Ended
| July 1, 2023 |  | July 2, 2022 |  | July 1, 2023 |  | July 2, 2022
Revenues |  |  |  |  |  |  |
Biotechnology | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Discontinued operations | — |  |  | 10,538 |  |  | 3,795 |  |  | 19,862 |
Total Revenues | $ | — |  |  | $ | 10,538 |  |  | $ | 3,795 |  |  | $ | 19,862 |
Gross profit |  |  |  |  |  |  |
Biotechnology | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Discontinued operations | — |  |  | 1,649 |  |  | (197) |  |  | 3,502 |
Total Gross profit | $ | — |  |  | $ | 1,649 |  |  | $ | (197) |  |  | $ | 3,502 |
Operating income (loss) |  |  |  |  |  |  |
Biotechnology | $ | (1,060) |  |  | $ | (658) |  |  | $ | (2,159) |  |  | $ | (1,339) |
Discontinued operations | — |  |  | 9,639 |  |  | 14,159 |  |  | 9,229 |
Total Operating income (loss) | $ | (1,060) |  |  | $ | 8,981 |  |  | $ | 12,000 |  |  | $ | 7,890 |
Depreciation and amortization |  |  |  |  |  |  |
Biotechnology | $ | 362 |  |  | $ | — |  |  | $ | 726 |  |  | $ | 2 |
Discontinued operations | — |  |  | 135 |  |  | 96 |  |  | 268 |
Total Depreciation and amortization | $ | 362 |  |  | $ | 135 |  |  | $ | 822 |  |  | $ | 270 |
Interest (income) expense, net |  |  |  |  |  |  |
Biotechnology | $ | (365) |  |  | $ | (167) |  |  | $ | (840) |  |  | $ | (165) |
Discontinued operations | — |  |  | 807 |  |  | 181 |  |  | 418 |
Total Interest expense, net | $ | (365) |  |  | $ | 640 |  |  | $ | (659) |  |  | $ | 253 |
Net income (loss) before income taxes |  |  |  |  |  |  |
Biotechnology | $ | 62 |  |  | $ | (227) |  |  | $ | (827) |  |  | $ | 2,392 |
Discontinued operations | 1 |  |  | 9,105 |  |  | 13,976 |  |  | 7,700 |
Total Net income before income taxes | $ | 63 |  |  | $ | 8,878 |  |  | $ | 13,149 |  |  | $ | 10,092 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration